BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jun 26, 2006
 |  BioCentury  |  Strategy

Innate's TLR3 land grab

Innate Pharma S.A. says last week's deals with Schering-Plough Corp. and the Institut de Cancerologie Gustave Roussy give the company an opportunity to develop products in the toll-like receptor space, exploiting compounds where the mechanism of action already has been demonstrated. Two days after announcing the deals, the company proposed to go public on Euronext Paris(see "IPO Watch: Europe," A16).

Both deals cover toll-like receptor 3, which Innate plans to work on for TLR3-positive breast cancer.

In the first deal, Innate (Marseille, France) and SGP co-exclusively licensed IP covering TLR3. Each company received a limited right of first negotiation to co-develop and co-market the other's TLR3 products in certain regions.

In the second deal, Innate and IGR formed an R&D...

Read the full 607 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >